Browse All Grants
20,252 grants found
Showing 4,161 – 4,180 of 20,252 grants
Bacteria-derived xenobiotics in colon cancer prevention: Link to GPR109A and colonic ketogenesis
Project Summary: Chemical carcinogens and xenobiotics in the diet play a significant role in colon cancer (CC) formation. The intestinal tract, including the colon, is often the fi...
Preclinical and Clinical Models of Drug Induced Kidney Injury
PROJECT SUMMARY/ABSTRACT Immune checkpoint inhibitors (ICIs) are biologic drugs that have revolutionized cancer treatment by targeting specific inhibitory receptors, or their ligan...
Integrating Clinical, Pathologic, and Immune Features to Predict Breast Cancer Recurrence and Chemotherapy Benefit
Abstract Breast cancer is the leading cause of cancer death for women globally, with over 2.3 million cases diagnosed each year. Most cases are hormone receptor positive and effect...
Targeting RAGE in tumor and TME to oppose inflammation and drug resistance in obesity associated ER+ breast cancer
PROJECT SUMMARY/ABSTRACT Obesity is associated with increased postmenopausal estrogen receptor-positive (ER+) breast cancer (BC) risk and a 2-4 fold increase in mortality from all...
Bacteria-derived xenobiotics in colon cancer prevention: Link to GPR109A and colonic ketogenesis
Project Summary: Chemical carcinogens and xenobiotics in the diet play a significant role in colon cancer (CC) formation. The intestinal tract, including the colon, is often the fi...
Neutrophil derived proteinases abolish the IFNG signature in NSCLC
ABSTRACT Although immune checkpoint inhibitor (ICI) therapy has been a tremendous clinical success, just ~20% of non- small cell lung cancer (NSCLC) patients respond to anti-PD1/PD...
Preclinical and Clinical Models of Drug Induced Kidney Injury
PROJECT SUMMARY/ABSTRACT Immune checkpoint inhibitors (ICIs) are biologic drugs that have revolutionized cancer treatment by targeting specific inhibitory receptors, or their ligan...
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
A Novel VpreB1 Antibody-Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignanc...
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment
Pancreatic ductal adenocarcinoma (PDAC) represents a therapy recalcitrant disease with 5-year survival rate of approximately 10%. Multiple failed clinical trials reinforce the need...
Identifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approaches
PROJECT SUMMARY Conventional prostate adenocarcinoma (PCa) is the second leading cause of cancer death in American men. Patients with organ-confined disease are candidates for pote...
Epigenetic regulation of pancreatic cancer subtype identity and tumorigenesis by PHF2
Molecular subtyping of pancreatic ductal adenocarcinoma (PDAC) has defined two major transcriptional subtypes, Classical and Basal-like, which are presently the most powerful predi...
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL
PROJECT SUMMARY The Epstein-Barr Virus (EBV) is responsible for approximately 200,000 new cancer cases each year worldwide. Among these, EBV+ Diffuse Large B-Cell Lymphoma (DLBCL)...
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities
Breast cancer remains a major killer of women due to the ineffectiveness of current drugs against metastatic and drug-resistant cancers. Additionally, African American (AA) women s...
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
Prostate cancer (PC) is the second leading cause of cancer-related death among American men, and the vast majority of these deaths are due to metastatic, castration-resistant PC (m...
Profiling the Fluid Assisted Dissemination of Pre-malignant cells in Fallopian Tubes
PROJECT SUMMARY The high mortality rate in ovarian cancers is explained in part, by late-stage clinical diagnosis where intraperitoneal tumor burden is already prevalent and widesp...
The role of focal adhesion kinase in therapy resistant prostate tumors
Abstract Treatment-induced neuroendocrine prostate cancer (t-NEPC) is a subgroup of prostate tumors with poor patient outcomes. Beyond systemic chemotherapy and palliative care, no...
Overcoming mechanisms of therapeutic resistance in pancreatic ductal adenocarcinoma
PROJECT SUMMARY – Overall While mortality rates for many cancers are declining, pancreatic ductal adenocarcinoma (PDA) remains a highly lethal malignancy with the worst 5-year surv...
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
PROJECT SUMMARY – Project 1: Epigenetics Pancreatic ductal adenocarcinoma (PDA) is a devastating disease with a disturbing rise in incidence. The poor prognosis of PDA is attribute...
Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer
PROJECT SUMMARY – Project 2: Signaling Pancreatic ductal adenocarcinoma (PDA) is most commonly diagnosed at late stages, at which time the disease is refractory to most conventiona...
Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma
PROJECT SUMMARY – Project 3: Autophagy Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest forms of cancer with few effective therapies. The poor performance of current...